Page 7 - Inhalation Solution News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Market Insights, Epidemiology, and Market Forecast-2030″  report delivers an in-depth understanding of the Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) , historical and forecasted epidemiology as well as the Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.   Some of the PH-ILD facts: According to Somnath Pal et al., 12 million people in the United States ...

Aurobindo Pharma’s Tobramycin Inhalation Solution is an AB-rated generic equivalent to the reference Tobi Inhalation Solution.

United Therapeutics Announces New England Journal of Medicine Publication of the INCREASE Study Evaluating Tyvaso® in Pulmonary Hypertension Associated with Interstitial Lung Disease INCREASE Study is First to Demonstrate a Clear Benefit in Patients with PH-ILD, a Life-threatening Disease with No Currently FDA-Approved Treatments Company to host a webcast detailing the INCREASE study results on Tuesday, January 19, 2021 at 4:30 p.m. E.T. News provided by Share this article Share this article SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Jan. 13, 2021 /PRNewswire/ -- United Therapeuti...

Polyphor Receives Approval to Start First-in-Human Clinical Trial of Inhaled Antibiotic Murepavadin December 22, 2020 01:30 ET | Source: Polyphor AG Polyphor AG Allschwil, SWITZERLAND Phase I safety, tolerability, and pharmacokinetic study in healthy volunteers expected to start in coming weeks following acceptance of a request for a Clinical Trial Authorization (CTA) granted by the UK Medicines and Healthcare products Regulatory Agency (MHRA). Polyphor’s inhaled murepavadin is a novel class antibiotic that specifically targets Pseudomonas aerug...